Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioCryst ( (BCRX) ) has issued an update.
On October 1, 2025, BioCryst Pharmaceuticals completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with potential future milestones of up to $14 million. This transaction allows BioCryst to focus on its U.S. operations, improve its operating margin, and retire a significant portion of its debt, positioning the company for future strategic activities. Neopharmed Gentili will handle the commercialization of ORLADEYO in Europe, ensuring continuity for the brand and patients.
The most recent analyst rating on (BCRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s overall stock score is primarily impacted by its financial instability and weak technical indicators. However, the strong performance and strategic outlook from the earnings call provide a positive counterbalance, highlighting potential for future growth.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of people with hereditary angioedema and other rare diseases. The company specializes in structure-guided drug design to develop oral small-molecule and protein therapeutics, including ORLADEYO®, the first oral, once-daily plasma kallikrein inhibitor.
Average Trading Volume: 2,895,016
Technical Sentiment Signal: Sell
Current Market Cap: $1.58B
For a thorough assessment of BCRX stock, go to TipRanks’ Stock Analysis page.